CN107635583A - 用于治疗癌症的方法、组合物和试剂盒 - Google Patents

用于治疗癌症的方法、组合物和试剂盒 Download PDF

Info

Publication number
CN107635583A
CN107635583A CN201680022780.7A CN201680022780A CN107635583A CN 107635583 A CN107635583 A CN 107635583A CN 201680022780 A CN201680022780 A CN 201680022780A CN 107635583 A CN107635583 A CN 107635583A
Authority
CN
China
Prior art keywords
fgfr3
inhibitor
seq
antibody
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680022780.7A
Other languages
English (en)
Chinese (zh)
Inventor
约瑟林·赫拉什
史蒂芬·刘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rainier Therapeutics Inc
Original Assignee
Bioclin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioclin Therapeutics Inc filed Critical Bioclin Therapeutics Inc
Publication of CN107635583A publication Critical patent/CN107635583A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680022780.7A 2015-02-19 2016-02-19 用于治疗癌症的方法、组合物和试剂盒 Pending CN107635583A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562118350P 2015-02-19 2015-02-19
US62/118,350 2015-02-19
US201562150235P 2015-04-20 2015-04-20
US62/150,235 2015-04-20
PCT/US2016/018634 WO2016134234A1 (en) 2015-02-19 2016-02-19 Methods, compositions, and kits for treatment of cancer

Publications (1)

Publication Number Publication Date
CN107635583A true CN107635583A (zh) 2018-01-26

Family

ID=56689191

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680022780.7A Pending CN107635583A (zh) 2015-02-19 2016-02-19 用于治疗癌症的方法、组合物和试剂盒

Country Status (12)

Country Link
US (1) US20160243228A1 (cg-RX-API-DMAC7.html)
EP (1) EP3258966A4 (cg-RX-API-DMAC7.html)
JP (2) JP6774421B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170137717A (cg-RX-API-DMAC7.html)
CN (1) CN107635583A (cg-RX-API-DMAC7.html)
AU (2) AU2016219917B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017017700A2 (cg-RX-API-DMAC7.html)
CA (1) CA2976638A1 (cg-RX-API-DMAC7.html)
IL (1) IL253979B (cg-RX-API-DMAC7.html)
MX (1) MX2017010595A (cg-RX-API-DMAC7.html)
SG (1) SG11201706727XA (cg-RX-API-DMAC7.html)
WO (1) WO2016134234A1 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108440673A (zh) * 2018-04-08 2018-08-24 海南医学院 Fc融合蛋白PD1/FGFR1及其应用
CN113710244A (zh) * 2019-06-03 2021-11-26 融合制药公司 用于治疗癌症的方法和组合物
CN114466662A (zh) * 2019-09-26 2022-05-10 詹森药业有限公司 在fgfr遗传改变的癌症中使用fgfr抑制剂以增强患者在序贯治疗设置中对免疫检查点抑制剂的反应
CN116390757A (zh) * 2020-10-28 2023-07-04 卫材R&D管理有限公司 用于治疗肿瘤的药物组合物

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120553A1 (es) 2009-03-25 2012-05-18 Genentech Inc Anticuerpos anti-fgfr3
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
RU2715236C2 (ru) 2014-03-26 2020-02-26 Астекс Терапьютикс Лтд Комбинации
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
HUE053653T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR inhibitor és IGF1R inhibitor kombinációi
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
JP6898919B2 (ja) 2015-09-23 2021-07-07 ヤンセン ファーマシューティカ エヌ．ベー． 新規化合物
US11542247B2 (en) 2015-09-23 2023-01-03 Janssen Pharmaceutica Nv Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer
CN115177619A (zh) 2015-12-17 2022-10-14 卫材R&D管理有限公司 用于乳腺癌的治疗剂
KR20200026787A (ko) * 2017-02-06 2020-03-11 레이니어 테라퓨틱스, 인크. 암 치료를 위한 방법, 조성물, 및 키트
US20200277387A1 (en) * 2019-03-01 2020-09-03 Rainier Therapeutics, Inc. Methods and compositions for treating cancer
BR112022019226A2 (pt) * 2020-03-23 2022-11-08 Fusion Pharmaceuticals Inc Radioimunoconjugados direcionados a fgfr3 e usos dos mesmos
US11505611B2 (en) 2020-08-21 2022-11-22 Genzyme Corporation FGFR3 antibodies and methods of use
WO2024152014A1 (en) 2023-01-13 2024-07-18 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100247531A1 (en) * 2009-03-25 2010-09-30 Genentech, Inc. Anti-fgfr3 antibodies and methods using same
US20140030259A1 (en) * 2012-07-27 2014-01-30 Genentech, Inc. Methods of treating fgfr3 related conditions
US20140243308A1 (en) * 2010-12-22 2014-08-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2015009856A2 (en) * 2013-07-16 2015-01-22 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI381848B (zh) * 2008-10-20 2013-01-11 Imclone Llc 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100247531A1 (en) * 2009-03-25 2010-09-30 Genentech, Inc. Anti-fgfr3 antibodies and methods using same
US20140243308A1 (en) * 2010-12-22 2014-08-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
US20140030259A1 (en) * 2012-07-27 2014-01-30 Genentech, Inc. Methods of treating fgfr3 related conditions
WO2015009856A2 (en) * 2013-07-16 2015-01-22 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
STÉPHANE CHAMPIAT ET AL.: "Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC", 《J THORAC ONCOL.》 *
孙燕、石远凯主编: "《中国肿瘤内科进展》", 31 August 2011, 中国协和医科大学出版社 *
真有书屋: "2014年药物研发最热门靶点逐个评述", 《个人图书馆HTTP://WWW.360DOC.COM/CONTENT/14/1010/13/17132703_415769463.SHTML》 *
罗斯（ROTH, J. A.）主编: "《肺癌》", 31 March 2011, 世界图书出版西安有限公司 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108440673A (zh) * 2018-04-08 2018-08-24 海南医学院 Fc融合蛋白PD1/FGFR1及其应用
CN113710244A (zh) * 2019-06-03 2021-11-26 融合制药公司 用于治疗癌症的方法和组合物
CN114466662A (zh) * 2019-09-26 2022-05-10 詹森药业有限公司 在fgfr遗传改变的癌症中使用fgfr抑制剂以增强患者在序贯治疗设置中对免疫检查点抑制剂的反应
CN116390757A (zh) * 2020-10-28 2023-07-04 卫材R&D管理有限公司 用于治疗肿瘤的药物组合物

Also Published As

Publication number Publication date
IL253979B (en) 2021-06-30
AU2022200196B2 (en) 2025-04-10
BR112017017700A2 (pt) 2018-07-31
US20160243228A1 (en) 2016-08-25
JP6774421B2 (ja) 2020-10-21
JP2018507220A (ja) 2018-03-15
IL253979A0 (en) 2017-10-31
MX2017010595A (es) 2018-11-12
JP7122357B2 (ja) 2022-08-19
EP3258966A1 (en) 2017-12-27
SG11201706727XA (en) 2017-09-28
JP2021020909A (ja) 2021-02-18
WO2016134234A1 (en) 2016-08-25
AU2016219917B2 (en) 2021-12-16
NZ735243A (en) 2024-11-29
AU2022200196A1 (en) 2022-02-10
EP3258966A4 (en) 2018-07-25
KR20170137717A (ko) 2017-12-13
CA2976638A1 (en) 2016-08-25
AU2016219917A1 (en) 2017-09-07

Similar Documents

Publication Publication Date Title
AU2022200196B2 (en) Methods, compositions, and kits for treatment of cancer
TWI780994B (zh) 用於治療非小細胞肺癌之抗b7-h1及抗ctla-4抗體
KR102595561B1 (ko) Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법
TWI795347B (zh) 使用抗ｐｄ-１抗體與抗ｃｔｌａ-４抗體之組合以治療肺癌
KR20170122809A (ko) 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
US20200308286A1 (en) Methods, compositions, and kits for treatment of cancer
EP3137502A1 (en) Humanized antibodies against ceacam1
US11572405B2 (en) Combination therapy with anti-IL-8 antibodies and anti-PD-1 antibodies for treating cancer
KR20170007750A (ko) Ｈｐｖ-음성 암의 치료를 위한 ｐｄｌ-1의 길항제 및 ｐｄ-1의 길항제
JP2025060639A (ja) Ｐｄ－１／ｐｄ－ｌ１シグナル伝達阻害剤に不応答性のがんの処置方法および医薬
KR20230093282A (ko) 폐암에 대한 lag-3 길항제 요법
TW202417479A (zh) 用於治療癌症之抗-pd-1活性劑、抗-tim-3活性劑及抗-lag-3活性劑之組合療法
JP2019517507A (ja) 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ
CN117202934A (zh) 抗pd-1抗体联合一线化疗治疗晚期非小细胞肺癌的用途
US20230250182A1 (en) Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof
CN113473989B (zh) Sumo活化酶抑制剂和检查点抑制剂的施用
CN116406288A (zh) 使用PD-1拮抗剂、HIF-2α抑制剂、以及乐伐替尼或其药学上可接受的盐的组合，用于治疗癌症或冯-希佩尔-林道病的方法
KR20230069957A (ko) 암을 갖는 환자의 치료를 위한 pd-1 길항제 및 lag3 길항제 및 렌바티닙 또는 이의 약학적으로 허용가능한 염의 병용 요법
KR20250135324A (ko) 병용 요법을 위한 방법 및 조성물
CN112915202B (zh) 喹啉衍生物与pd-1单抗的药物组合
TW202508632A (zh) 使用抗ｐｄ－１及化學療法治療肺癌
TW202509063A (zh) 用抗lag3、抗pd-1和化學療法治療食管癌

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: American California

Applicant after: Reniel Medical Company

Address before: American California

Applicant before: Bioclinical medical company

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20200807

Address after: Ontario, Canada

Applicant after: Fusion pharmaceutical Co.

Address before: California, USA

Applicant before: Reniel Medical Co.